坦罗莫司治疗晚期肾细胞癌的研究进展
Advances in Temsirolimus for Treatment of Patients with Advanced Renal Cell Carcinoma
王润洁 1李江1
作者信息
- 1. 无锡市人民医院肿瘤科,无锡214023
- 折叠
摘要
坦罗莫司(Temsirolimus,CCI-779)是一种特异性mTOR抑制剂.在Ⅲ期临床研究中对晚期肾细胞癌具有良好的疗效,延长总生存期至10.9个月.其主要不良反应包括代谢失调(高血脂、高血糖)、黏膜炎、皮疹和肺炎等.2007年5月美国FDA批准坦罗莫司用于难治性晚期肾细胞癌的一线治疗,具有广泛的应用前景.
Abstract
Temsirliums is an specific inhibitor of the mammalian target of rapamycin (mTOR). This sirolimus derivative has shown clinical efficacy in monotherapy for poor-risk renal cell carcinoma (RCC) leading to an overall survival of 10.9 months in the pivotal phase III trial. Its specific adverse events consist of metabolic dysregulation (hyperlipemia, hyperglycemia), mucositis, rash and pneumonitis. The data from this pivotal trial were the basis for May 2007 FDA approval of temsirolimus for advanced RCC.
关键词
肾癌/坦罗莫司/疗效/不良反应Key words
Renal cell carcinoma/Temsirolimus/Efficacy/Adverse reactions引用本文复制引用
出版年
2011
NETL
NSTL
维普
万方数据